AH
Andrew E. Hendifar
Elite in Pancreatic Cancer

Dr. Andrew E. Hendifar

Samuel Oschin Cancer Center
Los Angeles, CA
Elite
 in Pancreatic Cancer
Specialties:Hematology Oncology | Oncology
Experience:20 Years
Clinical Trials:Currently Recruiting for 12 Trials
Accepts:New PatientsMedicare
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Andrew E. Hendifar's experience treating your condition:
About Dr. Andrew E. Hendifar

Andrew Hendifar is a Hematologist Oncology specialist and an Oncologist in Los Angeles, California. Hendifar has been practicing medicine for over 20 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 28 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Ductal Adenocarcinoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), and Endoscopy. He is licensed to treat patients in California. Hendifar is currently accepting new patients.

His clinical research consists of co-authoring 142 peer reviewed articles and participating in 26 clinical trials in the past 15 years. In particular, he has co-authored 58 articles and participated in 15 clinical trials in the study of Pancreatic Cancer.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Andrew E. Hendifar it is best to call his office and ask if your insurance is accepted.

Accepts Medicare
Call to see if your plan is accepted.
Locations
127 S San Vicente Blvd, 7th Floor, Los Angeles, CA 90048
Background & Education
Graduate Institution
Other, 2003
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: October 21, 2022
Intervention Type: Device, Drug
Study Drugs: GemcitabineNab-paclitaxel
Study Phase: Phase 3
IIT2021-16-Hendifar-KetoROCX: A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma
Enrollment Status: Recruiting
Publish Date: July 19, 2022
Intervention Type: Drug
Study Phase: Early Phase 1
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Enrollment Status: Recruiting
Publish Date: September 02, 2022
Intervention Type: Drug
Study Drugs: TelatinibKeytruda
Study Phase: Phase 2
Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: September 07, 2022
Intervention Type: Other
Study Phase: Not Applicable
BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation
Enrollment Status: Recruiting
Publish Date: December 07, 2022
Intervention Type: Drug
Study Drugs: BinimetinibEncorafenib
Study Phase: Phase 2
A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts
Enrollment Status: Recruiting
Publish Date: October 28, 2022
Intervention Type: Drug
Study Phase: Phase 1
Pancreatic-enzyme Replacement Therapy With Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency
Enrollment Status: Recruiting
Publish Date: July 19, 2022
Intervention Type: Drug
Study Drug: Pancrelipase
Study Phase: Phase 2
A Prospective, Single Center, Double Blind, Randomized, Crossover Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drug: Ketamine
Study Phase: Early Phase 1
IIT2020-02-Gong-GlutaPanc: Phase I Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer (GlutaPanc)
Enrollment Status: Recruiting
Publish Date: September 02, 2022
Intervention Type: Drug
Study Drugs: GemcitabineNab-PaclitaxelL-Glutamine
Study Phase: Phase 1
Precision Promise Platform Trial for Metastatic Pancreatic Cancer
Enrollment Status: Recruiting
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drugs: GemcitabineNab-paclitaxelSM-88mFOLFIRINOX
Study Phase: Phase 3
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
Enrollment Status: Recruiting
Publish Date: December 02, 2022
Intervention Type: Drug, Other
Study Drugs: CapecitabineCarboplatinCisplatinEtoposideTemozolomide
Study Phase: Phase 2
Digitally-Captured Step Counts for Evaluating Performance Status in Advanced Cancer Patients: A Single Cohort, Prospective Trial
Enrollment Status: Recruiting
Publish Date: March 31, 2022
Intervention Type: Other
A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: December 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Longitudinal, Single Institution Study Evaluating Weight Stability in Advanced Pancreatic Cancer Patients With Cachexia Who Are Receiving Enteral Feeding
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Other
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment
Enrollment Status: Active, not recruiting
Publish Date: May 26, 2022
Intervention Type: Drug
Study Phase: Phase 4
A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel®/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumour Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumours
Enrollment Status: Terminated
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Other, Biological, Drug
Study Drugs: PanitumumabRegorafenibTrifluridineTipiracil
Study Phase: Phase 2
IIT2018-26 -Hendifar-NETCx: A Descriptive, Multicenter, Single-arm, Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Enrollment Status: Withdrawn
Publish Date: December 30, 2020
Intervention Type: Drug
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
Enrollment Status: Active, not recruiting
Publish Date: September 28, 2022
Intervention Type: Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Unknown status
Publish Date: May 07, 2019
Intervention Type: Biological, Drug
Study Drugs: PEGPH20Pembrolizumab
Study Phase: Phase 2
A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
Enrollment Status: Active, not recruiting
Publish Date: May 26, 2022
Intervention Type: Drug, Other
Study Phase: Phase 3
An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II Study of Durvalumab (Medi 4736) and Stereotactic Ablative Body Radiotherapy in Locally Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active, not recruiting
Publish Date: August 12, 2022
Intervention Type: Drug, Radiation
Study Drug: Durvalumab
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials -
142 Total Publications
Tumor hyaluronan as a novel biomarker in non-small cell lung cancer: A retrospective study.
Journal: Oncotarget
Published: November 07, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
VC
Dr. Vincent M. Chung
Oncology | Hematology Oncology
Elite
Highly rated in
23
conditions
Oncology
Hematology Oncology

City of Hope

Duarte - Main Campus

1500 E Duarte Rd, 
Duarte, CA 
 23.6 mi

Vincent Chung is an Oncologist and a Hematologist Oncology expert in Duarte, California. Chung has been practicing medicine for over 25 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 23 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Ampullary Cancer, and Endoscopy. He is licensed to treat patients in California.

ZW
Dr. Zev A. Wainberg
Hematology Oncology | General Surgery
Elite
Highly rated in
20
conditions
Hematology Oncology
General Surgery

UCLA Health System

Santa Monica Cancer Care

2020 Santa Monica Blvd, 
Santa Monica, CA 
 6.6 mi

Zev Wainberg is a Hematologist Oncology specialist and a General Surgeon in Santa Monica, California. Wainberg has been practicing medicine for over 23 years and is rated as an Elite expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 20 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Stomach Cancer, Pancreatic Ductal Adenocarcinoma, and Tissue Biopsy. He is licensed to treat patients in California. Wainberg is currently accepting new patients.

WI
Dr. William H. Isacoff
Oncology | Hematology Oncology
Distinguished
Highly rated in
4
conditions
Oncology
Hematology Oncology

UCLA Health System

William H Isacoff MD Inc

10921 Wilshire Blvd, 
Los Angeles, CA 
 3.9 mi

William Isacoff is an Oncologist and a Hematologist Oncology expert in Los Angeles, California. Isacoff has been practicing medicine for over 53 years and is rated as a Distinguished expert by MediFind in the treatment of Pancreatic Cancer. He is also highly rated in 4 other conditions, according to our data. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, and Cholangiocarcinoma (Bile Duct Cancer). He is licensed to treat patients in California. Isacoff is currently accepting new patients.